Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact
Seven months ago, Thermo Fisher spent $1.7 billion to add a gene therapy company to its sprawling biotech business, purchasing Brammer Bio. Now they’ve signed a collaboration deal with another, newly well-funded, company from the same founder to expand its gene therapy work into the microbiome.
Thermo Fisher announced a collaboration with microbiome product manufacturer Arranta Bio as the startup announced an $82 million funding round. The young CDMO will provide its live biopharmaceuticals to Thermo Fisher to use in gene therapy production.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
